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Docosahexaenoic acid (DHA) is an n-3 fatty acid that is an important structural
component of the cell membrane. DHA exerts potent anti-inflammatory effects through
G protein-coupled receptor 120 (GPR120), which is a functional receptor for n-3 fatty
acids. DHA also regulates osteoclast formation and function. However, no studies
have investigated the effect of DHA on inflammation-induced osteoclast formation
in vivo. In the present study, we investigated whether DHA influences osteoclast
formation, bone resorption and the expression of osteoclast-associated cytokines
during lipopolysaccharide (LPS)-induced inflammation in vivo, and then we elucidated
the underlying mechanisms by using in vitro experiments. In vitro experiments
revealed both receptor activator of NF-kB ligand (RANKL)- and tumor necrosis
factor-α (TNF-α)-induced osteoclast formation was inhibited by DHA. Supracalvarial
administration of LPS with or without DHA was carried out for 5 days and then
the number of osteoclasts, ratio of bone resorption pits and the level of type I
collagen C-terminal cross-linked telopeptide were measured. All measurements
were significantly lower in LPS+DHA-co-administered mice than LPS-administered
mice. However, this DHA-induced inhibition was not observed in LPS-, DHA-, and
selective GPR120 antagonist AH7614-co-administered mice. Furthermore, the
expression of RANKL and TNF-α mRNAs was lower in the LPS+DHA-co-administered
group than in the LPS-administered group in vivo. TNF-α mRNA levels were
decreased in macrophages co-treated with LPS+DHA compared with cells
treated with LPS in vitro. In contrast, RANKL mRNA expression levels from
osteoblasts co-treated with DHA and LPS in vitro were equal to that in cells
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treated with LPS alone. Finally, the inhibitory effects of DHA on osteoclast formation
in vitro were not observed by using osteoclast precursors from GPR120-deficient
mice, and inhibition of LPS-induced osteoclast formation and bone resorption by DHA
in vivo was not observed in GPR120-deficient mice. These results suggest that DHA
inhibits LPS-induced osteoclast formation and bone resorption in vivo via GPR120 by
inhibiting LPS-induced TNF-α production in macrophages along with direct inhibition of
osteoclast formation.
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INTRODUCTION
Osteoclasts, which are specialized bone resorbing cells derived
from hematopoietic stem cells, play important roles in bone
remodeling and in bone destruction in diseases such as
rheumatoid arthritis, osteoporosis, and periodontal disease (1).
Two important cytokines, receptor activator of NF-kB ligand
(RANKL) and macrophage colony stimulating factor (M-CSF),
are required for osteoclast formation and osteoclast function (2).
M-CSF is also essential for proliferation of osteoclast precursors.
Tumor necrosis factor-α (TNF-α) has also been reported to
induce osteoclast formation both in vitro (3–5) and in vivo
(6, 7). TNF-α is central to pathological bone disorders including
inflammation (8).
Lipopolysaccharide (LPS), which is a major constituent of
the cell wall of Gram-negative bacteria, induces inflammation
and pathological bone destruction (9, 10). LPS also induces
the production of pro-inflammatory cytokines, such as TNF-
α from macrophages and other cells at sites of inflammation
(11, 12). Furthermore, LPS stimulates osteoblasts to produce and
express osteoclast-related cytokine RANKL (13). These cytokines
have been linked to LPS-induced osteoclast formation and bone
resorption in both in vivo and in vitro studies (9, 14).
It has been reported that polyunsaturated fatty acids
confer some beneficial effects on cardiovascular diseases
(15), autoimmune disorders and inflammatory disorders such
as rheumatoid arthritis, inflammatory bowel disease, and
dysmenorrhea (16, 17) and diabetes (18). Docosahexaenoic acid
(DHA), a well-known dietary n-3 polyunsaturated fatty acid,
is a long-chain polyunsaturated fatty acid that has 22 carbon
atoms and 6 double bonds. DHA is used as a food supplement
and has favorable effects against certain cancers, diabetes and
cardiovascular diseases (19, 20).
G protein-coupled receptors (GPRs) play a pivotal role as
signaling molecules for many cellular functions. G protein-
coupled receptors are seven transmembrane domain receptors
that regulate many physiological and pathological responses (21–
24). It has been reported that free fatty acids can activate receptors
GPR40 (free fatty acid receptor: FFAR1), GPR41 (FFAR3),
GPR43 (FFAR2), GPR84, and GPR120 (FFAR4) and long-chain
fatty acids can activate GPR40 and GPR120 (25, 26). GPR120,
also known as free fatty acid receptor 4 (FFAR4), has also
been implicated in homeostatic metabolic regulation in immune
processes and inflammatory in vivo (27). Therefore, GPRs are
leading targets for drug development for many human diseases.
Especially, GPR120 has gathered attention owing to its potential
role in the regulation of many inflammation-related diseases such
as diabetes and obesity (21, 26–31).
It has been reported that dietary n-3 fatty acids inhibit bone
loss in ovariectomized mice owing to their inhibitory effects on
osteoclast formation (32). Some studies showed the inhibitory
effects of DHA on osteoclast formation and activity in vitro. It
has been reported that DHA inhibits osteoclast formation and
function in human CD14+ monocytes (33). It has also been
shown the differential effects of DHA on osteoclast formation
in the murine monocytic cell line RAW 264.7 (34). These
in vitro studies give some insight into the effects of DHA on
osteoclast formation, however, the effects of DHA on osteoclast
formation in vivo remain unclear. Furthermore, the effects of
DHA through GPR120 on osteoclast formation in vivo have not
been investigated.
In the present study, we showed the effects of DHA on LPS-
induced osteoclast formation and bone resorption via GPR120
in a murine experimental model and elucidated the underlying
mechanisms by using in vitro experiments.
MATERIALS AND METHODS
Animals and Reagents
Eight- to ten-week-old male C57BL6/J mice were obtained
from CLEA Japan (Tokyo, Japan). C57BL6 mice bearing the
Ffar4-floxed gene were generated by an outsourced research
company (Transgenic Inc., Fukuoka, Japan) as schematically
illustrated in Supplementary Figure 1. In the conditional Ffar4-
targeting vector designed according to the recombineering-
based construct, two loxP sites were inserted into the introns
immediately upstream and downstream of the exon 1 such that
an FRT-containing neomycin resistance cassette was included in
the loxP-flanked region. The targeting vector was introduced into
ES cells, and homologous recombination-positive clones were
isolated and used for generating germline-chimeric mice by the
embryo aggregation method. Heterozygous mutant mice bearing
the homologous mutation were produced and bred with the
Flp mice (Jackson Laboratory, Bar Harbor, USA) to remove the
neomycin resistance cassette. To generate systemic Ffar4 knock
out mice [Ffar4(dE1/dE1) mice], the floxed mice were crossed
with transgenic mice expressing Cre -recombinase under the
control of the chicken actin promoter (CAG). All animal care and
experiments were conducted according to Tohoku University
rules and regulations. Four mice were randomly distributed
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in each experimental group. DHA (Sigma-Aldrich, St Louis,
MO, USA), Escherichia coli LPS (Sigma-Aldrich) and GPR120
antagonist AH7614 (Tocris Bioscience, Bristol, United Kingdom)
were used in this study. For in vitro study, recombinant mouse
RANKL (35) and TNF-α (6) were obtained as previously
described, and recombinant mouse M-CSF was prepared from
an M-CSF-expressing cell line (CMG14-12) (36).
Histological Analysis
In a previous study, daily subcutaneous supracalvarial
administration of 100 µg LPS to mouse calvariae for 5 days
significantly induced osteoclast formation (37, 38). Therefore,
we followed the same protocol, dose and LPS administration
period in this study. Four mice were randomly distributed
in each group and received daily subcutaneous injections of
phosphate-buffered saline (PBS; negative control group), LPS
(100 µg/day, positive control group), LPS (100 µg/day), and
DHA (100 µg/day) with or without AH7614 (100 µg/day) and
DHA (100 µg/day). Ffar4(dE1/dE1) mice were subjected to daily
subcutaneous injections of LPS (100 µg/day, positive control
group) and LPS (100 µg/day) and DHA (100 µg/day). Calvariae
were resected immediately after sacrifice on the 6th day. After
fixation in 4% PBS-buffered formaldehyde, all calvariae were
demineralized in 14% ethylenediaminetetraacetic acid (EDTA)
for 3 days. After dehydration, calvariae were embedded in
paraffin and sectioned perpendicular to the sagittal suture
(5-µm thickness) using a microtome (Leica, Wetzlar, Germany).
Sections were stained for tartrate-resistant acid phosphatase
(TRAP) and hematoxylin counterstain as previously described
(37, 38). Osteoclasts were identified as TRAP-positive cells
containing three or more nuclei. The number of osteoclasts
located at the mesenchyme of the sagittal suture was counted
in all slides as described previously (37, 38). In addition, the
percentage of interface of bone marrow space covered by
osteoclasts and the number of osteoclast of interface of bone
marrow space were histomorphometrically determined in
specimens derived from each sample.
Preparation of Osteoclast Precursors for
Osteoclast Formation
Osteoclast formation was evaluated as previously described
(37, 38). Briefly, femoral and tibial epiphyses from 8 to 10-
week-old male C57BL/6J mice were cut, and then the bone
marrow was flushed using a 25-gauge needle and syringe
prefilled with alpha-modified minimal essential medium (α-
MEM; Sigma-Aldrich). Harvested cells were then cultured in α-
MEM containing 10% fetal bovine serum, 100 IU/mL penicillin
G (Meiji Seika, Tokyo, Japan) and 100µg/mL streptomycin
(Meiji Seika) with M-CSF. Adherent cells were harvested using
trypsin-EDTA solution (Sigma-Aldrich). Harvested cells were
then cultured in the presence of M-CSF until they reached
confluency. Cells were recognized as osteoclast precursors.
Osteoclast precursors were seeded at 5 × 104 cells per 200 µL
of culture medium in a 96-well plate and cultured for 5 days
in medium containing M-CSF (100 ng/mL); M-CSF (100 ng/mL)
and RANKL (100 ng/mL) or TNF-α (100 ng/mL); M-CSF
(100 ng/mL), RANKL (100 ng/mL), or TNF-α (100 ng/mL), and
DHA (100 ng/mL) with or without AH7614 (100 ng/mL); or M-
CSF (100 ng/mL) and DHA (100 ng/mL). After fixation with 4%
PBS-buffered formaldehyde, cells were permeabilized with 0.2%
Triton X-100 and TRAP staining was performed to visualize
active osteoclasts. TRAP-positive cells containing three or more
nuclei were counted under a light microscope (37, 38).
Isolation of Murine Macrophages
Eight- to ten-week old C57BL/6J mice were sacrificed to obtain
peritoneal macrophages; 5mL sterile ice-cold PBS (pH 7.4) was
injected into the peritoneal cavity and then the fluid was aspirated
out to collect cells. Collected cells were incubated for 1 h and then
non-adherent cells were removed. Adherent cells were cultured
an additional 24 h and used as peritoneal macrophages (37, 38).
RNA Preparation and Real-Time
RT-PCR Analysis
Calvariae from in vivo experiments were frozen in liquid
nitrogen and crushed by Micro Smash MS-100R (Tomy
Seiko, Tokyo, Japan) in 800 µL TRIzol reagent (Invitrogen,
Carlsbad, CA) for each sample. Total RNA was extracted with
an RNeasy mini kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocol. Osteoblasts (Cosmo Bio, Tokyo, Japan)
or macrophages were cultured in culture medium supplemented
with PBS; LPS (100 ng/mL); LPS (100 ng/mL); and DHA
(100 ng/mL) with or without AH7614 (100 ng/mL); or DHA
(100 ng/mL). After 24 h culture, total RNA was extracted from
osteoblasts or peritoneal macrophages. cDNA was synthesized
for each sample from 2 µg total RNA with oligo-dT primers
(Invitrogen) and reverse transcriptase in a total volume reaction
of 20 µL. To assess the gene expression value, the Thermal
Cycler Dice Real Time System (Takara, Shiga, Japan) was used
for real-time RT-PCR. Each reaction comprised a total volume
of 25 µL containing 2 µL cDNA and 23 µL of a mixture of
SYBR Premix Ex Taq (Takara) and 50 pmol/µL primers. PCR
cycling conditions were as follows: 95◦C for 10 s for initial
denaturation followed by 45–60 amplification cycles, with each
cycle comprising a denaturation step of 95◦C for 5 s and then
an annealing step of 60◦C for 30 s. Relative expression levels of
RANKL and TNF-α mRNAs were calculated by normalization
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA
levels. Primer sequences used for cDNA amplification were as
follows: 5′-GGTGGAGCCAAAAGGGTCA-3′ and 5′-GGGG
GCTAAGCAGTTGGT-3′ for GAPDH; 5′-AGGCGGTGC
TTGTTCCTCA-3′ and 5′-AGGCGAGAAGATGATCTGA
CTGCC-3′ for TNF-α; and 5′-CCTGAGGCCAGCCATTT- 3′
and 5′-CTTGGCCCAGCCTCGAT-3′ for RANKL as already
reported (37, 38).
Analysis of Bone Resorption
To evaluate the bone resorption area, calvariae were fixed
in 4% PBS-buffered formaldehyde and then scanned with
microfocus computed tomography (CT) (ScanXmate-E090;
Comscan, Kanagawa, Japan). Three-dimensional images of the
calvariae were prepared using TRI/3D-BON64 software (RATOC
System Engineering, Tokyo, Japan), and the ratio of the bone
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FIGURE 1 | DHA inhibits RANKL- and TNF-α-induced osteoclast formation via GPR120 in vitro. (A) Microscopic images and numbers of TRAP-positive cells following
RANKL-induced osteoclast formation. Osteoclast precursors were cultured with M-CSF, M-CSF+RANKL, M-CSF+RANKL+DHA, or M-CSF+DHA for 5 days,
followed by staining with TRAP solution. (B) Microscopic images and numbers of TRAP-positive cells following TNF-α-induced osteoclast formation. Osteoclast
precursors were treated with M-CSF, M-CSF+TNF-α, M-CSF+TNF-α+DHA, or M-CSF+DHA for 5 days, followed by staining with TRAP solution. (C) Microscopic
images and numbers of TRAP-positive cells following RANKL-induced osteoclast formation under AH7614 treatment. Osteoclast precursors were cultured with
(Continued)
Frontiers in Endocrinology | www.frontiersin.org 4 March 2019 | Volume 10 | Article 157
Kishikawa et al. DHA Inhibits Osteoclast Formation
FIGURE 1 | M-CSF+RANKL, M-CSF+RANKL+DHA, or M-CSF+RANKL+DHA and various concentration of AH7614 (1,000, 100, 10, and 1 ng/mL). (D)
Microscopic photos and numbers of TRAP-positive cells following TNF-α-induced osteoclast formation under AH7614 treatment. Osteoclast precursors were cultured
with M-CSF+TNF-α, M-CSF+TNF-α+DHA, or M-CSF+TNF-α+DHA and various concentration of AH7614 (1,000, 100, 10, and 1 ng/mL). Data are expressed as
means ± SD (n = 4; **p < 0.01, *p < 0.05). Statistical significance was determined by Scheffe’s test. Scale bars = 100µm.
resorption area to the total area was measured using ImageJ
(NIH, Bethesda, MD) (37, 38).
Measurement of Serum C-Terminal
Telopeptide (CTX) of Type I Collagen
Serumwas obtained frommice after 5 days of daily supracalvarial
administration of PBS, LPS, LPS+DHA with or without AH7614
or DHA alone. Serum CTX levels were evaluated using a
mouse CTX assay kit (IDS, Tyne and Wear, UK) by measuring
absorbance at 450 nm using amicroplate reader (Remote Sunrise;
Tecan, Kawasaki, Japan) with a reference wavelength of 620 nm
(37, 38).
Statistical Analyses
All data are expressed as means ± standard deviation (SD).
Differences between groups were assessed using Scheffe’s test,
one-way ANOVA and the Turkey-Kramer test. Statistical
significance was assumed at a threshold of p < 0.05.
RESULTS
DHA Inhibits RANKL- and TNF-α-Induced
Osteoclast Formation via GPR120
Activation in vitro
First, we examined the influence of DHA on RANKL- and
TNF-α-induced osteoclast formation to clarify whether DHA
directly influences osteoclast precursor cells (Figures 1A,B).
A large number of TRAP-positive cells were noted among
osteoclast precursor cells cultured with M-CSF and RANKL
or TNF-α. In contrast, the number of TRAP-positive cells was
markedly decreased when cells were cultured with M-CSF and
RANKL or TNF-α with DHA. Then, we investigated whether the
inhibitory effect of DHA is diminished by GPR120 antagonist
AH7614 (Figures 1C,D). AH7614 dose-dependently increased
the number of TRAP-positive cells compared with cells cultured
with M-CSF and RANKL or TNF-α with DHA.
DHA Inhibits LPS-Induced Osteoclast
Formation via GPR120 Activation in vivo
To assess whether LPS-induced osteoclast formation is inhibited
by DHA via GPR120 in vivo, LPS and DHA with or without
AH7614 were injected into mouse calvariae. When LPS was
administered for 5 consecutive days, many large multinucleated
TRAP-positive cells were noted within the suture mesenchyme
of histological sections (Figure 2A), the higher percentage of
interface of bone marrow space covered by osteoclasts and the
higher number of osteoclast of interface of bone marrow space
were observed (Figure 2B). In contrast, the mean number of
TRAP-positive cells and the percentage of osteoclast area of
interface of bone marrow space were markedly decreased in the
LPS and DHA co-administered group compared with the LPS
group, while the inhibitory effect of DHA was attenuated by co-
administration with AH7614 (Figures 2A,B). Moreover, TRAP
mRNA levels were remarkably lower in the LPS and DHA group
than in LPS or LPS and DHA with AH7614 co-administered
groups (Figure 2C).
DHA Inhibits LPS-Induced Bone
Resorption via GPR120 Activation in vivo
The ratio of bone resorption area to total area in three-
dimensional images of mouse calvariae was evaluated and
compared in each group. Many bone destruction defects were
observed in the LPS group compared with the PBS or DHA
group. However, the bone destruction defects were significantly
reduced in the LPS and DHA co-administered group, which
was increased again in the LPS and DHA with AH7614 co-
administered group (Figures 3A,B). We next evaluated serum
CTX levels by using a mouse CTX assay kit. Serum CTX levels
in the LPS group were significantly increased compared with
those in the PBS or DHA group, although the LPS with DHA
group had significantly lower CTX levels than the LPS group
(Figure 3C). Additionally, serum CTX levels were significantly
increased in the LPS and DHA with AH7614 co-administered
group compared with the LPS and DHA group.
DHA Inhibits Expression of LPS-Induced
TNF-α and RANKL mRNAs in vivo
The expression levels of osteoclast-related cytokines in calvariae
were determined by using real-time RT-PCR (Figures 4A,B).
RANKL and TNF-α mRNA levels were significantly elevated
in the LPS group compared with the PBS group. In contrast,
RANKL and TNF-α mRNA expression levels were significantly
lower in the LPS and DHA group than those of the LPS
group. Furthermore, treatment with GPR120 antagonist AH7614
elevated RANKL and TNF-α mRNA expression levels compared
with the LPS and DHA group.
DHA Suppresses LPS-Induced TNF-α
Expression in Macrophages but Does Not
Inhibit RANKL Expression in Osteoblasts
To precisely determine how DHA inhibits osteoclast formation
via GPR120, we investigated RANKL mRNA expression levels
in osteoblasts in vitro. RANKL mRNA expression levels
were upregulated by LPS treatment compared with PBS or
DHA alone. However, osteoblasts treated with both LPS and
DHA demonstrated similar RANKL mRNA expression levels
compared with cells treated with LPS alone. Moreover, RANKL
mRNA expression levels were similar between the LPS and DHA
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FIGURE 2 | DHA inhibits LPS-induced osteoclast formation via GPR120 activation in vivo. (A) Histological sections of calvariae were prepared from C57/BL6 mice
following 5 days of supracalvarial administration of PBS, LPS (100 µg/day), LPS (100 µg/day)+DHA (100 µg/day), LPS (100 µg/day)+DHA (100 µg/day)+AH7614
(100 µg/day), or DHA (100 µg/day). Sections were stained with TRAP solution and hematoxylin for counterstaining was performed. TRAP-positive cells appeared dark
red. Scale bars = 100µm. Numbers of TRAP-positive cells in the suture mesenchyme of calvariae from mouse groups administered PBS, LPS, LPS+DHA;
(Continued)
Frontiers in Endocrinology | www.frontiersin.org 6 March 2019 | Volume 10 | Article 157
Kishikawa et al. DHA Inhibits Osteoclast Formation
FIGURE 2 | LPS+DHA+AH7614 or DHA. Data are shown as means ± SD. Statistical significance was determined by Scheffe’s test (n = 4; **p < 0.01, *p < 0.05).
(B) Histological sections of calvariae after 5 days of daily supracalvarial administration of PBS, LPS (100 µg/day), LPS (100 µg/day)+DHA (100 µg/day), LPS (100
µg/day)+DHA (100 µg/day)+AH7614 (100 µg/day), or DHA (100 µg/day). Sections were stained with TRAP solution and hematoxylin for counterstaining was
performed. The percentage of interface of bone marrow space covered by osteoclast and the number of TRAP-positive cells per millimeter of interface of bone
marrow space were evaluated. Data is expressed as means ± standard deviation (SD). Statistical significance was determined by Scheffe’s test (n = 4; **p < 0.01
*p < 0.05). (C) Expression levels of TRAP mRNA in calvariae of the mouse groups determined by real-time RT-PCR analysis. Data are expressed as means ± SD.
Statistical significance was determined by one-way ANOVA and Turkey-Kramer tests (n = 4; **p < 0.01, *p < 0.05).
with AH7614 co-administered group and the LPS and DHA
group (Figure 5A).
We next investigated whether DHA inhibits LPS-induced
TNF-α expression in macrophages in vitro. TNF-α mRNA
expression levels were upregulated by LPS treatment, while
they were decreased by LPS and DHA treatment. Moreover,
treatment with GPR120 antagonist AH7614 significantly
increased TNF-α mRNA expression levels compared with LPS
and DHA (Figure 5B).
DHA Does Not Suppress LPS-Induced
Osteoclast Formation, Bone Resorption
and Production of Osteoclast-Related
Cytokines (TNF-α and RANKL) in
Ffar4(dE1/dE1) Mice
To clarify the role of GPR120 in osteoclast formation, we
generated and used Ffar4 knockout mice [Ffar4(dE1/dE1)].
Osteoclast precursor cells from Ffar4(dE1/dE1) mice were treated
with M-CSF, M-CSF, and RANKL with or without DHA or DHA
alone, and then the number of TRAP-positive cells was counted.
The number of TRAP-positive cells was increased in the M-CSF
and RANKL group. However, there was no significant difference
in the number of TRAP-positive cells between the M-CSF and
RANKL with DHA group and the RANKL group (Figure 6A).
Similar results were observed in osteoclast formation following
TNF-α and DHA treatment (Figure 6B).
We also evaluated osteoclast formation in vivo using
Ffar4(dE1/dE1) mice. Supracalvarial administration of LPS with
or without DHA was carried out for 5 days, and then the
number of TRAP-positive cells at the mesenchyme of the sagittal
suture was counted. Furthermore, the percentage of interface of
bone marrow space covered by osteoclasts and the number of
osteoclast of interface of bone marrow space were evaluated. In
the LPS group, a great number of TRAP-positive cells and the
higher percentage of osteoclast area of interface of bone marrow
space was observed in both wild type and Ffar4(dE1/dE1) mice.
There was no difference in the number of TRAP-positive cells
and the percentage of osteoclast area of interface of bone marrow
space between the LPS and DHA co-administrated group and
the LPS group. However, the number of TRAP-positive cells and
percentage of osteoclast area of interface of bone marrow space
were decreased in the LPS and DHA co-administrated group
compared with that of wild type mice (Figures 6C,D). There is
no significant difference of osteoclast number and percentage of
osteoclast area in both PBS injected wild type and Ffar4(dE1/dE1)
mice as control (Supplementary Figure 2).
Finally, we investigated bone resorption in Ffar4(dE1/dE1) mice
by using microfocus CT. There was no significant difference
between the ratio of bone resorption area in wild type and
Ffar4(dE1/dE1) mice administered LPS alone. In contrast, a
marked decrease was observed in the ratio of bone resorption
area in wild type mice co-administered LPS and DHA, while
no significant change was observed in Ffar4(dE1/dE1) mice co-
administered LPS and DHA compared with respective mice that
received LPS alone (Figure 6E).
DISCUSSION
Favorable effect of food intake and supplement of n-3 fatty acids
such as DHA were provided against skeletal disorders such as
osteoporosis and rheumatoid arthritis (19, 20). There are some
in vitro studies of effect of DHA on osteoclast formation by
using RAW264.7 cell (34, 39) and human CD14+ monocytes
(33). GPR120, which is one of the cell surface receptor, has an
important role in the regulation of inflammation. Therefore,
GPR120 is being watched with keep interest as one of the
potential therapeutic target in several inflammatory disorders. In
this study, we showed that DHA inhibits LPS-induced osteoclast
formation and bone resorption in vivo via GPR120 by inhibiting
LPS-induced TNF-α production in macrophages and directly
inhibiting osteoclast formation.
In the present study, we focused on GPR120, because several
studies showed GPR120 is highly expressed in RAW264.7
cells, intraperitoneal macrophages, osteoclast precursors and
osteoclast (27, 40, 41). It has been reported that DHA can activate
not only GPR120 but also GPR40 (42). GPR40 activation by using
its selective agonist GW9508 by blocked osteoclast formation
(43). However, Kim et al. reported that GPR120 was highly
expressed but GPR40 is very low in osteoclast precursors and
osteoclast (41). Therefore, we thought that GPR120 might play
important role in osteoclast formation and function.
Several studies showed that DHA inhibits osteoclast
formation in vitro. Kim et al. reported that DHA inhibits
RANKL-induced osteoclast formation in primary murine
macrophages by suppressing the activation of NF-kB and
MAPKs (44). Sun et al. also showed that DHA inhibits RANKL-
induced osteoclast formation in bone marrow macrophages
(32). Furthermore, DHA reduces RANKL-induced osteoclast
formation in RAW 264.7 cells (34, 39) by inhibition of c-Fos
expression (34). It has also been reported that DHA inhibits
osteoclast formation and function in human CD14+ monocytes
(33). In the present study, we initially investigated whether DHA
can inhibit RANKL- and TNF-α-induced osteoclast formation
by directly affecting osteoclast precursors in vitro. Our results
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FIGURE 3 | DHA inhibits LPS-induced bone resorption via GPR120 activation in vivo. (A) Micro-CT reconstruction images of calvariae. Images of calvariae resected
from mice after 5 days of daily supracalvarial administration of PBS, LPS (100 µg/day), LPS (100 µg/day)+DHA (100 µg/day), LPS (100 µg/day)+DHA (100
µg/day)+AH7614 (100 µg/day), or DHA (100 µg/day). Arrows indicate bone resorption areas and red areas indicate extensive bone resorption. (B) Ratio of bone
resorption area to total bone area. Results are expressed as means ± SD (n = 4; **p < 0.01, *p < 0.05). Differences were determined by Scheffe’s test. (C) Serum
CTX levels in vivo. Serum was prepared from mice following 5 days of daily supracalvarial administration of PBS, LPS (100 µg/day), LPS (100 µg/day)+DHA (100
µg/day), LPS (100 µg/day)+DHA (100 µg/day)+AH7614 (100 µg/day), or DHA (100 µg/day). Enzyme-linked immunosorbent assays was performed to determine
concentrations of circulating CTX. Data are shown as means ± SD (n = 4; **p < 0.01, *p < 0.05). Differences were determined by one-way ANOVA and
Turkey-Kramer tests.
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FIGURE 4 | DHA inhibits expression of LPS-induced TNF-α and RANKL via
GPR120 in vivo. (A) Expression levels of RANKL mRNA in mouse calvariae
in vivo. (B) Expression levels of TNF-α mRNA in mouse calvariae in vivo. TNF-α
and RANKL mRNA levels were determined using real-time RT-PCR. Total RNA
from mouse calvariae was isolated after 5 days of daily supracalvarial
injections of PBS, LPS (100 µg/day), LPS (100 µg/day)+DHA (100 µg/day)
with or without AH7614 (100 µg/day) and DHA (100 µg/day). Expression
levels of RANKL and TNF-α mRNA were normalized to that of GAPDH. Data
are shown as means ± SD (n = 4; **p < 0.01, *p < 0.05). Differences were
determined by one-way ANOVA and Tukey-Kramer tests.
indicated that DHA directly inhibited RANKL- and TNF-α-
induced differentiation of osteoclast precursors. In addition,
we investigated whether DHA inhibits RANKL- and TNF-α-
induced osteoclast formation via GPR120 activation by using
GPR120 antagonist AH7614 in vitro. AH7614 dose-dependently
FIGURE 5 | DHA suppresses LPS-induced TNF-α mRNA expression in
macrophages but does not affect LPS-induced RANKL mRNA expression in
osteoblasts. (A) Osteoblasts from cranial bone were incubated with PBS, LPS,
LPS+DHA with or without AH7614, or DHA alone. After 24-h culture, total
RNA was isolated and RANKL mRNA levels were determined using real-time
RT-PCR. (B) Peritoneal macrophages were cultured with PBS, LPS,
LPS+DHA with or without AH7614 or DHA alone. After 24-h culture, total RNA
was isolated and TNF-α mRNA levels were determined using real-time
RT-PCR. RANKL and TNF-α mRNA levels were normalized to that of GAPDH.
Data are expressed as means ± SD (n = 4; **p < 0.01, *p < 0.05). Differences
were determined by one-way ANOVA and Turkey-Kramer tests.
increased the number of TRAP-positive cells in both RANKL-
and TNF-α-induced osteoclast formation in cells cultured with
DHA. These results suggested that DHA inhibits osteoclast
formation via GPR120 in vitro.
It has been reported that DHA inhibits bone loss in
ovariectomized mice owing to its inhibition of osteoclast
generation and activation in vivo (32). In addition, perinatal
DHA supplementation is associated with decreased bone
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FIGURE 6 | DHA does not suppress LPS-induced osteoclast formation, bone resorption and production of osteoclast-related cytokines (TNF-α and RANKL) in
Ffar4(dE1/dE1) mice. (A) Microscopic images and numbers of TRAP-positive cells. Osteoclast precursor cells from Ffar4(dE1/dE1) mice were treated with M-CSF,
M-CSF+RANKL with or without DHA or DHA alone. TRAP staining was performed and TRAP-positive cells were counted. (B) Microscopic images and numbers of
TRAP-positive cells. Osteoclast precursor cells from Ffar4(dE1/dE1) mice were treated with M-CSF, M-CSF+TNF-α with or without DHA or DHA alone, and then TRAP
staining was performed. TRAP-positive cells were counted. Scale bars =100µm. (C) Histological sections of calvariae were prepared from Ffar4(dE1/dE1) mice after 5
days of daily supracalvarial administration of LPS (100 µg/day) with or without DHA (100 µg/day). Sections were stained with TRAP solution and hematoxylin
counterstaining was performed. TRAP-positive cells were counted. Scale bars =100µm. (D) Histological sections of calvariae were prepared from Ffar4dE1/dE1 mice
after 5 days of daily supracalvarial administration of LPS (100 µg/day) with or without DHA (100 µg/day). The percentage of interface of bone marrow space covered
by osteoclast and the number of TRAP-positive cell per millimeter of interface of bone marrow space were evaluated. (E) Micro-CT reconstruction images of calvariae.
Images of calvariae excised from Ffar4(dE1/dE1) mice after 5 days of daily supracalvarial administration of LPS (100 µg/day) with or without DHA (100 µg/day). Arrows
indicate bone resorption areas and red areas indicate extensive bone resorption. Data are shown as means ± SD (n = 4; **p < 0.01, *p < 0.05). Differences were
determined by Scheffe’s test.
Frontiers in Endocrinology | www.frontiersin.org 10 March 2019 | Volume 10 | Article 157
Kishikawa et al. DHA Inhibits Osteoclast Formation
FIGURE 7 | Putative model of the inhibitory effect of GPR120 activation by DHA in LPS-induced osteoclast formation and production of osteoclast-related cytokines
(RANKL and TNF-α) in vivo. Both RANKL and TNF-α have essential roles in inducing osteoclast differentiation. When osteoclast precursors are treated with RANKL,
TRAP-positive pre-osteoclasts are induced. These cells fuse and differentiate into osteoclasts under the influence of RANKL, subsequently inducing bone resorption.
TNF-α acts in a similar manner as RANKL to induce osteoclast differentiation. These cytokines also affect LPS-induced osteoclast formation and bone resorption
in vivo. LPS administration induces RANKL expression in osteoblasts and TNF-α expression in macrophages. Furthermore, LPS-induced TNF-α production increases
RANKL expression in osteoblasts. GPR120 activation directly inhibits osteoclast precursor differentiation and LPS-induced TNF-α expression in macrophages.
However, the inhibitory effect of GPR120 may be unrelated to RANKL expression in osteoblasts.
resorption, decreased osteoclast density and a higher bone
mass in rats (45). Periodontitis rats, which are generated
by oral infection of Porphyromonas gingivalis, treated with
fish oil containing DHA had signified less alveolar bone
resorption (46). In this study, DHA inhibited osteoclast
formation induced by LPS. Daily supracalvarial administration
of 100 µg of DHA for 5 days inhibited LPS-induced osteoclast
formation in vivo. The inhibitory effect of DHA on bone
resorption induced by LPS was also evaluated. The increase
in bone resorption was evaluated using the ratio of the bone
resorption area to total area in microfocus CT images. We
also determined bone destruction by evaluating the serum
CTX level. The increase in bone resorption was significantly
lower in the LPS and DHA group than in the LPS group.
These results indicated that DHA inhibits LPS-induced osteoclast
formation and bone destruction in vivo. The results of the
effect of DHA on osteoclast formation are similar to those
reported in previous studies (33, 34, 39, 44). Furthermore,
AH7614 increased osteoclast formation and bone resorption
in the LPS and DHA group. Taken together, these results
indicated that DHA inhibits LPS-induced osteoclast formation
via GPR120 in vivo.
Several reports showed that DHA inhibits pro-inflammatory
cytokine production from several cell types. DHA can inhibit
TNF-α and interleukin (IL)-6 production in primary mouse
macrophages and RAW 247.6 cells by binding to GPR120
(27). DHA also reduces LPS-induced production of pro-
inflammatory cytokines, such as TNF-α, IL-1β, and IL-6, in
THP-1 macrophages (47). Furthermore, DHA reduces IL-1β
expression in bone marrow-derived macrophages (48). We
suspect that the mechanisms of inhibitory effect of LPS-induced
osteoclast formation and bone resorption in vivo by DHA
are conceivable via either of two possible mechanisms. One
possible mechanism is DHA blocks expression of LPS-induced
cytokines associated with osteoclast formation. It is well-known
that RANKL and TNF-α are important factors in osteoclast
formation (2, 6, 7). Several groups showed that LPS is able
to induce TNF-α and RANKL expression in vivo (13, 49, 50).
In the present study, TNF-α and RANKL mRNA expression
levels were increased in LPS-treated mice. On the other hand,
TNF-α and RANKL mRNA expression was suppressed in
DHA and LPS co-administered mice in comparison with LPS-
treated mice. Our results were consistent with the hypothesis
that DHA inhibits osteoclast formation by suppressing the
expression of LPS-induced production of osteoclast-associated
cytokines. Another possible mechanism of DHA inhibition is
that DHA directly suppresses osteoclast formation by influencing
cell differentiation. Our results indicated that DHA directly
inhibited both RANKL- and TNF-α-induced differentiation of
osteoclast precursor cells into osteoclasts. Moreover, AH7614
increased the concentration of osteoclast-related cytokines in
LPS and DHA-treated mice. The results suggested that DHA
inhibited LPS-induced production of osteoclast-related cytokines
via GPR120 in vivo. These results indicated that the inhibitory
effects of DHA on osteoclast formation by LPS in vivo are
due to both decreased production of osteoclast-associated
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cytokines and direct actions of DHA on osteoclast precursors
through GPR120.
Next, we evaluated whether DHA inhibits LPS-induced
TNF-α mRNA expression in macrophages. The results indicated
that downregulation of TNF-α mRNA by DHA might result
from a direct action of DHA on macrophages. AH7614 increased
LPS-induced TNF-α mRNA expression in macrophages with
DHA treatment. Therefore, the results suggested that DHA
inhibited LPS-induced TNF-α in macrophages via GPR120.
In addition, we investigated the influence of DHA on LPS-
induced RANKL expression in osteoblasts, but no effect of
DHA on LPS-induced RANKL expression was found. Our
results suggested that DHA likely suppresses LPS-induced
osteoclast formation in vivo by directly inhibiting LPS-
induced TNF-α expression in macrophages. This inhibition
subsequently blocks RANKL expression in osteoblasts,
although there is no effect of DHA on LPS-induced RANKL
expression in osteoblasts, in addition to direct inhibition of
osteoclast formation.
Finally, we evaluated whether both RANKL- and TNF-α-
induced osteoclast formation is inhibited by DHA through
GPR120 and whether DHA inhibits LPS-induced osteoclast
formation and bone resorption in vivo via GPR120 by using
GPR120-deficient mice. The effects of DHA on osteoclast
formation in vitro disappeared by using osteoclast precursors
from GPR120-deficient mice and inhibition of LPS-induced
osteoclast formation and bone resorption by DHA in vivo
disappeared in GPR120-deficient mice. The results strongly
suggested that the effect of DHA on osteoclast formation in vivo
and in vitro was maintained via GPR120.
In conclusion, we demonstrated that DHA inhibits LPS-
induced osteoclast formation and bone destruction in vivo
and directly inhibits RANKL- and TNF-α-induced osteoclast
formation in vitro. The underlying mechanisms by which DHA
inhibits LPS-induced osteoclast formation and bone destruction
in vivo were associated with its inhibition of LPS-induced TNF-α
production inmacrophages and direct inhibition of RANKL- and
TNF-α-induced osteoclast formation via GPR120 (Figure 7).
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